Stoke Therapeutics Files 8-K

Ticker: STOK · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1623526

Stoke Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyStoke Therapeutics, Inc. (STOK)
Form Type8-K
Filed DateMar 25, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Stoke Therapeutics filed an 8-K on 3/25/24 for Reg FD and financials.

AI Summary

Stoke Therapeutics, Inc. filed an 8-K on March 25, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as ASOthera Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Bedford, Massachusetts.

Why It Matters

This filing indicates routine corporate reporting, including financial updates and disclosures, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This is a standard corporate filing with no immediate material events disclosed.

Key Numbers

  • 001-38938 — Commission File Number (Identifies the company's SEC filing history.)
  • 47-1144582 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Stoke Therapeutics, Inc. (company) — Registrant
  • ASOthera Pharmaceuticals, Inc. (company) — Former Name
  • March 25, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • Bedford, Massachusetts (location) — Principal Executive Offices

FAQ

What specific information is being disclosed under Regulation FD?

The filing does not specify the exact nature of the Regulation FD disclosure, only that it is being reported.

What financial statements and exhibits are included in this filing?

The filing indicates that Financial Statements and Exhibits are included, but the specific details are not provided in this summary.

When was Stoke Therapeutics, Inc. formerly known as ASOthera Pharmaceuticals, Inc.?

The date of the name change from ASOthera Pharmaceuticals, Inc. to Stoke Therapeutics, Inc. was October 28, 2014.

What is the principal executive office address for Stoke Therapeutics, Inc.?

The principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts, 01730.

What is the primary business of Stoke Therapeutics, Inc. according to its SIC code?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-25 16:07:39

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated March 25, 2024 99.2 Presentation, dated as of March 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STOKE THERAPEUTICS, INC. Date: March 25, 2024 By: /s/ Stephen J. Tulipano Stephen J. Tulipano Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.